Akèy › Sistèm Imunitè ak Twoub › Pennsylvania › Philadelphia
Etid klinik pou Sistèm Imunitè ak Twoub nan Philadelphia, PA
10 etid pou Sistèm Imunitè ak Twoub ap chèche patisipan nan sit nan ak bò kote Philadelphia (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
- Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program, Philadelphia
- Lewis Katz School of Medicine at Temple University, Philadelphia
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Ap rekriteEtid obsèvasyon
- Philadelphia Veterans Administration Medical Center, Philadelphia
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi lwen
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi lwen
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Ap rekriteFaz 3
- Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program, Philadelphia
- Lewis Katz School of Medicine at Temple University, Philadelphia
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Ap rekriteFaz 1/2
- Thomas Jefferson University, Philadelphia
Abatacept for the Treatment of Giant Cell Arteritis
Ap rekriteFaz 3
- University of Pennsylvania, Philadelphia
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Ap rekriteFaz 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
Ap rekriteFaz 2
- Children's Hospital of Philadelphia, Philadelphia
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Ap rekriteFaz 1/2
- Nemours Children's Health, Wilmington · 25 mi lwen
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Ap rekriteFaz 1/2
- University of Pennsylvania, Philadelphia
Etid Sistèm Imunitè ak Twoub nan lòt vil
- Washington, DC13 etid
- New York City, NY12 etid
- Boston, MA10 etid
- Portland, OR9 etid
- Atlanta, GA9 etid
- Houston, TX9 etid
- Chicago, IL8 etid
- Los Angeles, CA8 etid
- Cleveland, OH8 etid
- Seattle, WA6 etid
- Milwaukee, WI6 etid
- Cedar Rapids, IA6 etid
Lòt etid nan Philadelphia
- Kansè (tout kalite)59 etid
- Kansè nan tete56 etid
- Kansè Poumon ki pa ti selil51 etid
- Kansè Metastatik46 etid
- Kansè kolorektal44 etid
- Kansè ovè44 etid
- Kansè pwostat44 etid
- Kansè poumon36 etid
- Leksemi mieloïd egi34 etid
- Ensifizyans kadyak31 etid
- Kansè Endomèt28 etid
- Depresyon26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.